Drug Stock In Focus After FDA Resubmission

Short interest is high on OCUL

Managing Editor
Jun 29, 2018 at 10:10 AM
facebook X logo linkedin

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) are down 2.2% at $7.09 in early trading, after the company announced its New Drug Application (NDA) resubmission for its eye pain drug DEXTENZA, to the Food and Drug Administration (FDA). The company's President and CEO Antony Mattessich said it has made "substantial improvements" in the manufacturing of the pain drug.

Looking at the charts, Ocular Therapeutix stock has been trending higher since November, with pullbacks in recent months contained by the 50-day moving average. Overall, the drug concern has gained nearly 59% year-to-date.

Digging deeper, analyst sentiment has been extremely optimistic toward OCUL. As of yesterday, all six brokerage firms following the stock sport "strong buy" recommendations, while Ocular Therapeutix stock's average 12-month price target stands at $20.33 -- almost triple current levels.

Finally, short interest rose 2.7% during the most recent reporting period, and now represents nearly 20% of the stock's total available float. At OCUL's average price of daily trading, it would take over two weeks for shorts to cover their bearish bets.


How to collect 1 dividend check every day for LIFE

Did you know you could collect 1 dividend check every day the market is open? You could also do it starting with just $605! For me, I'm collecting 70 dividend checks every quarter…which averages around 1.1 dividend checks every business day. There's no trading behind this... no penny stocks or high-risk investments. All you do is buy and hold and you're set. There's no set up required either. If you start buying the dividend stocks I show you today... you could collect 1 dividend per day starting as early as this week. Click here for all the details.